濮阳东方医院收费与服务濮阳东方看妇科病靠谱吗,濮阳东方妇科口碑高,濮阳东方医院妇科做人流便宜,濮阳东方医院男科在哪,濮阳市东方医院挂号电话,濮阳东方男科医院咨询免费,濮阳东方妇科在哪里

SAN DIEGO (KGTV) — The City of San Diego could go to court to invalidate a landmark pension reform measure that voters overwhelmingly supported in 2012.The City Council is expected to meet in closed session the week June 10 to decide whether to ask a judge to throw out Measure B. The measure switched most new hires from pensions to 401(k) style retirement plans. More than 65 percent of San Diego voters supported Measure B in 2012. The problem, however, is that the measure got to the ballot via a citizens initiative, but then-Mayor Jerry Sanders campaigned on its behalf. Labor unions challenged the initiative in court, contending the mayor's involvement meant the city needed to meet and confer with them. The state Supreme Court agreed, and an appellate court ordered the city to make its employees whole, plus pay them 7 percent interest. The courts, however, did not invalidate Measure B, instead directing the city to work out a compromise with the unions. On Thursday, City Councilman Scott Sherman and former Councilman Carl DeMaio held a news conference pushing the city to protect Measure B."Right now we are being asked to go against what our bosses told us, and I don't think we should do that," Sherman said, adding that the city spends 0 million a year now meeting its minimum pension obligations. DeMaio said he would work with a coalition to go to court to protect Measure B. "I'm talking about putting the City of San Diego back on the brink of bankruptcy, let alone telling voters that they don't have a say on where their tax dollars go," he said. Early estimates indicate the amount needed to make employees whole ranges from negligible to million.Michael Zucchet, who heads the Municipal Employees Association, said the only rational way to move forward is to invalidate Measure B."It is time for the City and its citizens to move forward by ending the Prop B debacle with the least amount of additional litigation and expense, and at the same time help address the City’s severe recruitment and retention challenges brought about because San Diego is the only City in California with no defined benefit pension nor Social Security benefits for newly hired employees," Zucchet said in a statement.Mayor Kevin Faulconer said in a statement he would oppose any effort to get rid of Measure B. "Voters demanded pension reform and we should respect that, plain and simple," Faulconer said. The mayor cannot vote, however, in the decision facing the City Council. 2500

SAN DIEGO (KGTV) -- The Anti-Defamation League in San Diego announced a reward Thursday for information leading to the arrest of a suspect who reportedly shot at the Temple Emanu-El in Del Cerro. According to the ADL, the temple became aware that the building had been struck by bullets in “recent days.” When exactly the building was targeted is unclear. The league says the bullet holes were discovered in a portion of the building not in use. San Diego Police are also investigating the incident, but the ADL says they don’t believe there is a “known continuing threat to Temple Emanu-El or other Jewish institutions in the area.”“ADL takes any report of violence against a religious institution extremely seriously, and will always commit our utmost effort and resources to securing justice for victims,” said Tammy Gillies, ADL San Diego Regional Director. “We hope that by offering this reward, someone with critical information for investigators will be motivated to speak out.“According to the ADL, 2018 saw a 27 percent increase in anti-Semitic incidents throughout California. The league is offering a ,000 reward for information leading to an arrest. Anyone with information is asked to call the San Diego Police Department's Eastern Division at 858-495-7900. 1280

SAN DIEGO (KGTV) – The coronavirus has touched the lives of people of all ages, but none more than seniors. Despite ongoing challenges, residents at a senior living facility are finding ways to stay positive.You can’t see their smiles but you can tell they’re there.Residents at Belmont Village Senior Living in Sabre Springs are not only adapting to the pandemic, they’re overcoming it through "The Joys of Life."Don Bodow started the program to spread happiness and stimulate minds. Through a series of puzzles, games, and activities he helps fellow residents stay positive.“I’m making other people happy,” said Bodow. “Giving them joy simply makes me feel good.”Although they can’t be with their families during the pandemic, many are happy right where they are.“The joy of life is in all of us,” said Bodow. “We may not realize it and it needs to be brought out. You need to accept the fact that there are joys in your life.”One of his most active students is 98-year-old Pauline Hayes.“Some of those words are misspelled and you’re challenged to find them,” said Hayes. “I love doing Joys of Life.”Hayes attends every session and credits the class for keeping her sharp. When we asked her about the secret to life she replied, “keeping positive and keeping active.”Bodow says the program was built on his own experience after spending two months in a coma.“I lost all my memory, all my muscle mass. I had to learn how to walk again,” said Bodow.He’s made an incredible comeback while helping others along the way.“This is never about me,” said Bodow. “It’s making the other people happy, giving them a sense of a full life.”Through the challenges of COVID-19, Joys of Life is touching the lives of residents and staff like never before.Bodow has a collection of puzzles and games on his website. You can check them out here. 1837

SAN DIEGO (KGTV) - The invisible wounds of war are a heavy burden to carry, long after deployment. Tom Voss, an Army veteran who served in a scout-sniper platoon, knows this feeling well. "I took shrapnel to the head from a rocket-propelled grenade. And then I also had a lot of survivors guilt around the death of my platoon sergeant because that day I was given the day off," said Voss.He says while deployed, there's no time to process these war injuries. "You have a lot of these questions come up, years and years later. A lot of veterans struggle with, could I have done more, can I be forgiven? A lot of these moral questions," said Voss.After serving, he wanted to bury the traumas of war; in the beginning, he was incapable of dealing with the stresses caused by combat experience. "I was using alcohol and then on top of it abusing the medications that were given to me to kind of numb myself to the experiences, because I didn't know how to process them or move through them or move on from them on my own," said Voss. "I had a lot of suicidal ideations, so that's getting to the point of like, how am I going to take my own life?"Voss decided he needed to make a drastic change. He and a fellow veteran walked 2,700 miles across the country, from Wisconsin to California. It was on that trek where he began to heal and learned about holistic approaches to deal with trauma, like meditation and yoga. Voss now travels the world, teaching veterans and their families these techniques. "It's really up to us as veterans to educate the community about the experiences of what it's really like in combat and how it impacts veterans coming home, how it impacts communities, coming home. And most importantly, how it impacts families," said Voss. Voss chronicled his trek across the country in a memoir Where War Ends.It's available through Amazon, Barnes and Noble, and most places where books are sold. 1917

SAN DIEGO (KGTV) — The Department of Defense has awarded a San Diego biotech company up to million to help develop a next-generation drug to fight COVID-19.Sorrento Therapeutics calls the drug a “rapid countermeasure” against the disease, one that might serve as a vaccine substitute in certain populations or a critical stopgap tool if the virus mutates.“With this, we have a new platform potentially that can respond very quickly to any type of emerging threat,” said CEO Dr. Henry Ji.Sorrento is trying to become the first company to develop an approved DNA-encoded monoclonal antibody treatment. The approach is similar to the experimental monoclonal antibody treatment used on President Trump, but Sorrento’s concept is a more advanced version that offers several benefits.Sorrento’s drug is designed to be used as either a treatment in infected patients or a fast-forming layer of defense in healthy people. The company said its solution should be cheaper and easier to deploy than existing monoclonal antibodies, while offering vaccine-like protective effects that last for several months rather than just two or three weeks.Antibodies are one of the body’s key defense mechanisms. They seek out pathogens and bind to them, marking the invader for destruction like ground troops marking an enemy base for an airstrike. In some cases, antibodies can even neutralize an invader themselves by blocking its method of entry into cells.Monoclonal antibodies are antibodies designed by scientists to neutralize a pathogen. They are hand-picked, genetically modified super antibodies that are cloned in labs.However, the process of growing these super soldiers in the lab is difficult, transporting them requires a cold chain, and as a result, monoclonal antibodies are among the most expensive drugs in the world.Instead of giving people an infusion of pre-made antibodies, Sorrento’s idea is to give people a shot of DNA that instructs some of their cells to churn out perfectly pre-designed antibodies.“It's much easier to make enough DNA to treat a large number of people than it is to make enough protein to treat a large number of people. That’s just a fact about manufacturing,” said Dr. Robert Allen, Sorrento’s chief scientific officer on the project.Dr. Allen said the company is hopeful the drug will induce cells to make protective antibodies for six months or more.This DNA approach to an antibody treatment has never been approved for any disease but other companies are working on their own versions of it. Another biotech with ties to San Diego, Inovio Pharmaceuticals, became the first company to test this approach in humans in 2019 for a drug targeting the Zika virus.Sorrento’s approach is similar to the way DNA vaccines work, but it cuts out intermediary steps and jumpstarts the production of antibodies, rather than leaving the production of antibodies up to the body’s immune system. The result is that protective antibodies can start circulating in days after injection rather than weeks, the company said.“What this is capable of doing is it bypasses the need for the immune system,” said Dr. Mark Brunswick, Sorrento’s senior vice president for regulatory affairs.The drug is unlikely to replace a vaccine in most situations because vaccines can produce other defense mechanisms like T-cells that work in conjunction with antibodies. But the drug might work better than a vaccine for the elderly and others with weakened immune systems who are unable to produce a robust number of antibodies on their own, Brunswick said.Still, the company still has a lot of pre-clinical work and testing to go. Sorrento is hoping to have the drug ready for human trials in four to six months.By then, vaccines from Pfizer and Moderna will likely be widely available, but Dr. Ji said the world needs to prepare for the possibility this virus will mutate.“When you vaccinate hundreds of millions, potentially billions of people, the virus is under tremendous evolution pressure,” he said. “It will escape. It’s guaranteed that the virus is going to mutate and escape all of the vaccines we’re trying to create.”If it does, he said Sorrento will be ready to rapidly deploy its DNA-based countermeasure. 4223